At the American Epilepsy Society (AES) Annual Meeting in Washington, DC (December 1-5), Elekta (booth #1207) announced that the new commercial name for its MEG business is MEGIN and also introduced its latest-generation magnetoencephalography (MEG) platform for investigating human brain activity, TRIUX™ neo*.
“As part of the new growth strategy for the Elekta MEG business, the new commercial brand identity – which is closely tied to the Elekta Group – will help us deliver the growth-specific message to our stakeholders and more closely identify us to neurology and neurophysiology users,” says Janne Huhtala, CEO and Senior Vice President and Head of Global MEG Business, Elekta Oy. “I’m very proud to present MEGIN as our new brand. Elekta is the acknowledged leader of the industry and now we can not only execute our growth strategy, but do so with the strong support of our parent company.”
Elekta is the leading supplier of MEG technology, with 115 delivered MEG systems worldwide and a 28-year track record of bringing leading solutions to the market since its inception in 1989, and supporter of the global MEG community.
TRIUX neo introduced as latest generation of MEG platform
The most notable new features of TRIUX neo are:
- ARMOR™ electronics that deliver better signal quality with less noise and complete MEG platform together with previously announced ARMOR sensors
- Enhanced performance in noisy environments
“This technological milestone in the evolution of TRIUX integrates an optimized design that will expand the capabilities of our MEG platform, while maintaining full clinical compatibility with workflows and protocols based on thousands of patients,” says Janne Hämäläinen, Product Manager, MEG.
MEG is based on the detection of the very weak magnetic fields that originate from electrical activity within the brain. These signals are detected with a SQUID (superconducting quantum interference device) array placed close to the scalp.
MEG is used to localize both epileptic activity between seizures and important healthy tissues in the cortex that must be preserved during surgery. Thus MEG can be used to plan the placement of intracranial electrodes. MEG functional mapping has proven clinically useful to evaluate epilepsy and to perform presurgical mapping of visual, auditory, somatosensory and motor cortex areas. Accurate localization of cortical tissues is useful also when performing other types of surgery, such as tumor removal.
MEG research applications include exploring the neural basis of developmental disorders like Autism, as well as psychiatric and neurodegenerative diseases. Investigators also use MEG to address basic questions about brain functions, such as memory, attention, emotion, language and social cognition, abilities that are frequently disrupted by brain disorders.
*TRIUX™ neo is a works in progress and not yet available for sale or distribution.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, Email: email@example.com
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, Email: firstname.lastname@example.org
Time zone: EST: Eastern Standard Time
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com